AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8823899 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganzfeld perceptual field with 2 sec. interstimulus interval
Number of subjects: 143
Study 8823899 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganzfeld perceptual field with 3 sec. interstimulus interval
Number of subjects: 143
Study 8823899 — intervention group
Group type: COMPARATOR
Intervention: Control group (clear plastic lenses)
Number of subjects: 143
Study 1313369 — intervention group
Group type: EXPERIMENTAL
Intervention: Cessation of smoking after myocardial infarction
Number of subjects: 1755
Study 1313369 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma fibrinogen levels
Number of subjects: 1755
Study 1313369 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma viscosity, white blood cell count, haemoglobin, mean platelet volume
Number of subjects: 1755
Study 2865093 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 micrograms SMS
Number of subjects: 10
Study 2865093 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 micrograms SMS
Number of subjects: 10
Study 2865093 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 2865093 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS
Number of subjects: 10
Study 31203109 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm responsiveness to toddler fear
Number of subjects: 55
Study 31203109 — intervention group
Group type: EXPERIMENTAL
Intervention: Both warmth and prompt to engage
Number of subjects: 55
Study 31203109 — intervention group
Group type: COMPARATOR
Intervention: No-encouragement control
Number of subjects: 55
Study 30091814 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic Education System (TES), an internet-based psychosocial intervention for substance use disorders.
Number of subjects: 507
Study 30091814 — intervention group
Group type: COMPARATOR
Intervention: Therapeutic Education System (TES) and treatment-as-usual (control).
Number of subjects: 507
Study 30091814 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (control).
Number of subjects: 507
Study 27418551 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate (FF)/umeclidinium (UMEC)/vilanterol (VI)
Number of subjects: 10000
Study 27418551 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone furoate (FF)/vilanterol (VI)
Number of subjects: 10000
Study 27418551 — intervention group
Group type: COMPARATOR
Intervention: Umeclidinium (UMEC)/vilanterol (VI)
Number of subjects: 10000
Study 27678137 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation-based training (SBT) before operating room apprenticeship (SIM-OR group)
Number of subjects: 143
Study 27678137 — intervention group
Group type: COMPARATOR
Intervention: Simulation-based training (SBT) after operating room apprenticeship (OR-SIM group)
Number of subjects: 143
Study 27678137 — intervention group
Group type: EXPERIMENTAL
Intervention: Difference in cumulative score from day 1 to day 4 for SIM-OR group
Number of subjects: 143
Study 27678137 — intervention group
Group type: COMPARATOR
Intervention: Difference in cumulative score from day 1 to day 4 for OR-SIM group
Number of subjects: 143
Study 22795281 — intervention group
Group type: EXPERIMENTAL
Intervention: Pexelizumab
Number of subjects: 356
Study 22795281 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 356
Study 22795281 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell culture with pexelizumab
Number of subjects: 356
Study 20507926 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth Education Program (TEP) - ten 1-hr sessions
Number of subjects: 158
Study 20507926 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 158
Study 20507926 — intervention group
Group type: EXPERIMENTAL
Intervention: TEP
Number of subjects: 158
Study 18498916 — intervention group
Group type: EXPERIMENTAL
Intervention: MPA AUC(0‐12h) ranges >60 mg/L x h(‐1)
Number of subjects: 100
Study 18498916 — intervention group
Group type: EXPERIMENTAL
Intervention: MPA AUC(0‐12h) ranges <30 mg/L x h(‐1), 30‐60 mg/L x h(‐1), >60 mg/L x h(‐1)
Number of subjects: 100
Study 18498916 — intervention group
Group type: EXPERIMENTAL
Intervention: MPA AUC(0‐12h)
Number of subjects: 100
Study 18498916 — intervention group
Group type: EXPERIMENTAL
Intervention: MPA AUC(0‐12 h)
Number of subjects: 100
Study 18498916 — intervention group
Group type: EXPERIMENTAL
Intervention: MPA AUC(0‐12 h) ranges <30, 30‐60, >60 mg/L x h(‐1)
Number of subjects: 100
Study 15914981 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride-containing slow-release device (SFG)
Number of subjects: 174
Study 15914981 — intervention group
Group type: COMPARATOR
Intervention: Control (non-fluoride slow-release device)
Number of subjects: 174
Study 12848637 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (10 mg)
Number of subjects: 10
Study 12848637 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 10561191 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF + EPO
Number of subjects: 50
Study 10561191 — intervention group
Group type: COMPARATOR
Intervention: G-CSF
Number of subjects: 50
Study 10561191 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF and G-CSF + EPO
Number of subjects: 50
Study 8777066 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance group received calls twice a month for six months
Number of subjects: 115
Study 8777066 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 115
Study 8777066 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance group with > or = 5 lb weight loss and 10% TC decrease
Number of subjects: 115
Study 8777066 — intervention group
Group type: COMPARATOR
Intervention: Control group with > or = 5 lb weight loss and 10% TC decrease
Number of subjects: 115
Study 1890155 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg DHSP
Number of subjects: 12
Study 1890155 — intervention group
Group type: COMPARATOR
Intervention: 1 mg cyproterone acetate
Number of subjects: 12
Study 1890155 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 3882480 — intervention group
Group type: EXPERIMENTAL
Intervention: Squaric acid dibutyl ester (SADBE) treatment on the right side of the scalp
Number of subjects: 17
Study 3882480 — intervention group
Group type: COMPARATOR
Intervention: Untreated control on the left side of the scalp
Number of subjects: 17
Study 31718637 — intervention group
Group type: EXPERIMENTAL
Intervention: Antifibrotic drugs (10 patients treated with pirfenidone at 2403 mg/day, 1 patient with nintedanib at 300 mg/day)
Number of subjects: 11
Study 31718637 — intervention group
Group type: EXPERIMENTAL
Intervention: Antifibrotic drugs
Number of subjects: 11
Study 30630794 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined medication of abraxane and trastuzumab
Number of subjects: 80
Study 30630794 — intervention group
Group type: COMPARATOR
Intervention: Single medication of trastuzumab
Number of subjects: 80
Study 26975590 — intervention group
Group type: EXPERIMENTAL
Intervention: Early parenteral nutrition (initiated within 24 hours after ICU admission)
Number of subjects: 1440
Study 26975590 — intervention group
Group type: COMPARATOR
Intervention: Late parenteral nutrition (initiated on the morning of the 8th day in the ICU)
Number of subjects: 1440
Study 26975590 — intervention group
Group type: COMPARATOR
Intervention: Late parenteral nutrition
Number of subjects: 1440
Study 26975590 — intervention group
Group type: EXPERIMENTAL
Intervention: Early parenteral nutrition
Number of subjects: 1440
Study 23619160 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vitamin D₃ supplementation (2000 IU per day)
Number of subjects: 24
Study 23619160 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vitamin D₃ supplementation)
Number of subjects: 24
Study 19473280 — intervention group
Group type: EXPERIMENTAL
Intervention: Portuguese version of ID-Migraine™
Number of subjects: 142
Study 19473280 — intervention group
Group type: COMPARATOR
Intervention: Clinical diagnosis by neurologist (gold standard)
Number of subjects: 142
Study 16260696 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose tumor cell vaccine
Number of subjects: 64
Study 16260696 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose tumor cell vaccine
Number of subjects: 64
Study 12473479 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiseptic bonded central venous catheters (Arrowguard Arrow International)
Number of subjects: 181
Study 12473479 — intervention group
Group type: COMPARATOR
Intervention: Smooth pure polymer central venous catheters (Infectguard MedexMedical Ltd)
Number of subjects: 181
Study 9135409 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine penalisation
Number of subjects: 36
Study 9135409 — intervention group
Group type: COMPARATOR
Intervention: Occlusion therapy
Number of subjects: 36
Study 8034388 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal naloxone
Number of subjects: 17
Study 8034388 — intervention group
Group type: COMPARATOR
Intervention: Intravenous naloxone
Number of subjects: 17
Study 3283599 — intervention group
Group type: EXPERIMENTAL
Intervention: Primidone
Number of subjects: 13
Study 3283599 — intervention group
Group type: COMPARATOR
Intervention: Phenobarbital
Number of subjects: 13
Study 3283599 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 11320544 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic cholecystitis patients
Number of subjects: 48
Study 11320544 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 48
Study 30740698 — intervention group
Group type: EXPERIMENTAL
Intervention: Pono Choices curriculum
Number of subjects: 1783
Study 30740698 — intervention group
Group type: COMPARATOR
Intervention: Control schools
Number of subjects: 1783
Study 29502374 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib 150 mg per day for 9 weeks
Number of subjects: 86
Study 29502374 — intervention group
Group type: COMPARATOR
Intervention: Pemetrexed combined with cisplatin chemotherapy (2 cycles followed by 3-week discontinuation)
Number of subjects: 86
Study 29502374 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant targeted therapy group
Number of subjects: 86
Study 29502374 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy group
Number of subjects: 86
Study 26231973 — intervention group
Group type: EXPERIMENTAL
Intervention: Practical Resources for Effective Postpartum Parenting (PREPP)
Number of subjects: 54
Study 26231973 — intervention group
Group type: COMPARATOR
Intervention: Enhanced TAU (control group)
Number of subjects: 54
Study 25277614 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (4 g/day)
Number of subjects: 337
Study 25277614 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 337
Study 22490487 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance plus loading dose group (R + L): 200 mg aspirin and 150 mg clopidogrel per day
Number of subjects: 90
Study 22490487 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance plus routine dose group (R + R): 100 mg aspirin plus 75 mg clopidogrel per day
Number of subjects: 90
Study 22490487 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study 20018367 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mL of the pandemic vaccine (Fluval P, a monovalent vaccine with 6 microg haemagglutinin per 0.5 mL content and aluminium phosphate gel adjuvant; n=178)
Number of subjects: 355
Study 20018367 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mL of the pandemic vaccine and 0.5 mL of the seasonal trivalent vaccine (Fluval AB, a trivalent inactivated whole-virion influenza vaccine; n=177)
Number of subjects: 355
Study 20018367 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 355
Study 17373172 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% 5-fluorouracil cream
Number of subjects: 36
Study 17373172 — intervention group
Group type: COMPARATOR
Intervention: 5% imiquimod cream
Number of subjects: 36
Study 14984731 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic education and support
Number of subjects: 1050
Study 14984731 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive education and support
Number of subjects: 1050
Study 14984731 — intervention group
Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 1050
Study 11593109 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosinopril
Number of subjects: 241
Study 11593109 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine GITS
Number of subjects: 241
Study 9533423 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (captopril up to 100 mg/day + 5 mg bendrofluazide)
Number of subjects: 15
Study 9533423 — intervention group
Group type: COMPARATOR
Intervention: Captopril alone
Number of subjects: 15
Study 7583988 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy for symptomatic patients with stenosis 70% or greater
Number of subjects: 3
Study 7583988 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy for asymptomatic patients with stenosis 50% to 70%
Number of subjects: 3
Study 7583988 — intervention group
Group type: COMPARATOR
Intervention: Antiplatelet therapy
Number of subjects: 3
Study 2655909 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyazide (25 mg hydrochlorothiazide and 50 mg triamterene), one capsule daily for eight weeks
Number of subjects: 0
Study 2655909 — intervention group
Group type: COMPARATOR
Intervention: Placebo, one capsule daily for eight weeks
Number of subjects: 0
Study 29694815 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenecteplase (0.25 mg/kg, max 25 mg)
Number of subjects: 202
Study 29694815 — intervention group
Group type: COMPARATOR
Intervention: Alteplase (0.9 mg/kg, max 90 mg)
Number of subjects: 202
Study 29694815 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenecteplase
Number of subjects: 202
Study 29694815 — intervention group
Group type: COMPARATOR
Intervention: Alteplase
Number of subjects: 202
Study 27984412 — intervention group
Group type: EXPERIMENTAL
Intervention: Home blood pressure monitoring every 3 months
Number of subjects: 1733
Study 27984412 — intervention group
Group type: COMPARATOR
Intervention: Control group (office BP measured at 0, 12, and 24 months)
Number of subjects: 1733
Study 26031551 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise with whole-body vibration
Number of subjects: 19
Study 26031551 — intervention group
Group type: COMPARATOR
Intervention: Resistance exercise without whole-body vibration
Number of subjects: 19
Study 23206376 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcoholics Anonymous (AA) attendance
Number of subjects: 1726
Study 21751031 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior fusion with additional osteotomy (Group A)
Number of subjects: 24
Study 21751031 — intervention group
Group type: COMPARATOR
Intervention: Posterior fusion without additional osteotomy (Group B)
Number of subjects: 24
Study 21751031 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-related quality of life (HRQoL) parameters
Number of subjects: 24
Study 18081732 — intervention group
Group type: EXPERIMENTAL
Intervention: DDP733 0.5 mg
Number of subjects: 0
Study 18081732 — intervention group
Group type: EXPERIMENTAL
Intervention: DDP733 0.8 mg
Number of subjects: 0
Study 18081732 — intervention group
Group type: EXPERIMENTAL
Intervention: DDP733 1.4 mg
Number of subjects: 0
Study 18081732 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16609352 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated method for interpreting bone scans
Number of subjects: 200
Study 15080819 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus ointment (0.1%) given twice a day
Number of subjects: 30
Study 15080819 — intervention group
Group type: COMPARATOR
Intervention: Oral cyclosporine (3 mg/kg) given once daily
Number of subjects: 30
Study 11144051 — intervention group
Group type: EXPERIMENTAL
Intervention: Cockroach allergen sensitivity
Number of subjects: 160
Study 9101691 — intervention group
Group type: EXPERIMENTAL
Intervention: Cash inducement (£5 and £10)
Number of subjects: 1000
Study 9101691 — intervention group
Group type: EXPERIMENTAL
Intervention: Charity donation (£5 and £10)
Number of subjects: 1000
Study 9101691 — intervention group
Group type: COMPARATOR
Intervention: Control group (no inducement initially, then offered £5 or £10)
Number of subjects: 1000
Study 8517099 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone inhaler (50 micrograms)
Number of subjects: 120
Study 8517099 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine 10% spray
Number of subjects: 120
Study 2875621 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlormethiazole
Number of subjects: 0
Study 2875621 — intervention group
Group type: EXPERIMENTAL
Intervention: Temazepam
Number of subjects: 0
Study 28823213 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum 25(OH)D levels
Number of subjects: 174
Study 28823213 — intervention group
Group type: EXPERIMENTAL
Intervention: Female gender
Number of subjects: 174
Study 28823213 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 174
Study 28823213 — intervention group
Group type: EXPERIMENTAL
Intervention: Height
Number of subjects: 174
Study 28823213 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight
Number of subjects: 174
Study 28823213 — intervention group
Group type: EXPERIMENTAL
Intervention: Triceps skinfold thickness
Number of subjects: 174
Study 27931575 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorbable biliary stent placement
Number of subjects: 10
Study 27931575 — intervention group
Group type: COMPARATOR
Intervention: Control group (no stent placement)
Number of subjects: 10
Study 24885317 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone counselling intervention by pharmacist 2 or 3 weeks after a new prescription.
Number of subjects: 30
Study 24885317 — intervention group
Group type: COMPARATOR
Intervention: Usual care arm (control group).
Number of subjects: 30
Study 22245725 — intervention group
Group type: EXPERIMENTAL
Intervention: Red labeled cup
Number of subjects: 0
Study 22245725 — intervention group
Group type: EXPERIMENTAL
Intervention: Red plate
Number of subjects: 0
Study 22245725 — intervention group
Group type: COMPARATOR
Intervention: Blue labeled cup
Number of subjects: 0
Study 22245725 — intervention group
Group type: COMPARATOR
Intervention: Blue plate
Number of subjects: 0
Study 22245725 — intervention group
Group type: COMPARATOR
Intervention: White plate
Number of subjects: 0
Study 19330394 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-incision THA
Number of subjects: 21
Study 19330394 — intervention group
Group type: COMPARATOR
Intervention: Mini-posterior THA
Number of subjects: 21
Study 17952423 — intervention group
Group type: EXPERIMENTAL
Intervention: Halofantrine (500 mg) with kolanut (12.5 g)
Number of subjects: 15
Study 17952423 — intervention group
Group type: COMPARATOR
Intervention: Halofantrine (500 mg) alone
Number of subjects: 15
Study 17952423 — intervention group
Group type: EXPERIMENTAL
Intervention: Desbutylhalofantrine with kolanut
Number of subjects: 15
Study 17952423 — intervention group
Group type: COMPARATOR
Intervention: Desbutylhalofantrine alone
Number of subjects: 15
Study 16485516 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 0
Study 12439119 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole triple therapy (OAC: omeprazole 20 mg b.d., amoxicillin 1 g b.d., clarithromycin 0.5 g b.d.)
Number of subjects: 149
Study 12439119 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole quadruple therapy (OBMT: omeprazole 20 mg b.d., colloidal bismuth subcitrate 120 mg q.i.d., metronidazole 0.5 g t.i.d., tetracycline hydrochloride 0.5 g q.i.d.)
Number of subjects: 149
Study 12439119 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 149
Study 10203434 — intervention group
Group type: EXPERIMENTAL
Intervention: TAS changed every 48 h
Number of subjects: 166
Study 10203434 — intervention group
Group type: COMPARATOR
Intervention: TAS changed every 24 h
Number of subjects: 166
Study 7595749 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Number of subjects: 70
Study 7595749 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 2266673 — intervention group
Group type: EXPERIMENTAL
Intervention: L-lactate (46 mM)
Number of subjects: 0
Study 2266673 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicarbonate (35 mM + 4 mM acetate)
Number of subjects: 0
Study 2266673 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetate (39 mM)
Number of subjects: 0
Study 7420419 — intervention group
Group type: EXPERIMENTAL
Intervention: Restricted environmental stimulation therapy (lying on a bed in a dark, silent room) combined with self-management messages
Number of subjects: 48
Study 7420419 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management messages
Number of subjects: 48
Study 7420419 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced stimulation environment
Number of subjects: 48
Study 30503672 — intervention group
Group type: EXPERIMENTAL
Intervention: Current asthma symptoms prevalence
Number of subjects: 0
Study 30503672 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician-diagnosed asthma
Number of subjects: 0
Study 30503672 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe asthma and asthma with exercise
Number of subjects: 0
Study 30503672 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent consumption of meat and potatoes
Number of subjects: 0
Study 30503672 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent vigorous exercise
Number of subjects: 0
Study 30503672 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent exercise
Number of subjects: 0
Study 30503672 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental tobacco smoking
Number of subjects: 0
Study 30503672 — intervention group
Group type: EXPERIMENTAL
Intervention: Current active tobacco smoking
Number of subjects: 0
Study 30503672 — intervention group
Group type: EXPERIMENTAL
Intervention: Current wheezing and asthma diagnosis
Number of subjects: 0
Study 27721089 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured prebriefing
Number of subjects: 76
Study 27721089 — intervention group
Group type: COMPARATOR
Intervention: Traditional prebriefing activities
Number of subjects: 76
Study 26393386 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/day istradefylline plus sham‐rTMS
Number of subjects: 132
Study 26393386 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg/day istradefylline plus sham‐rTMS
Number of subjects: 132